Financial analysts tracking Outlook Therapeutics Inc. maintain varying twelve-month price forecasts for the biotechnology company, with consensus targets adjusted to reflect recent clinical and regulatory updates. While past forecasts climbed higher, current average targets hover around the four to five-dollar range, with individual projections varying from conservative minimums to highly optimistic maximum estimates. Because the firm operates in the volatile clinical-stage biopharmaceutical sector, target prices are heavily contingent upon regulatory milestones, commercialization progress, and future capital requirements.